ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Stoke Therapeutics (STOK) pipeline and stated timing

Name in SEC filings: Stoke Therapeutics, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
zorevunersen submissionPhase 3 20278-K ·
STK-002/data readoutPhase 1H1 20278-K ·

Source: ORION, orionbiotechai.com/company/STOK, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/STOK

Nearest upcoming stated timing: zorevunersen · NDA/BLA submission · Q1 2027

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

STK-002

Matched

Topline/data readoutH1 2027

Stage: Phase 1SEC filing · “Phase 1”

Public float: $592,000,000 · as of · SEC filing

Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027

8-K · Filed · Last checked

Source details

Accession 0001193125-26-330537

Alert me · Calendar: same stage and window-end month (2027-06)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
STK-002Clinical resultsH1 2027
“Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

zorevunersenSubmissionQ1 2027
“rolling U.S. NDA submission planned to initiate in Q1 2027”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch STOK

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for STOK. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See STOK in the calendar · Review labels and methodology

A New Drug Application (NDA) or Biologics License Application (BLA) asks the FDA to approve a drug or biologic for sale.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.Topline results are the main summary results of a clinical trial, released before the full data.